170 related articles for article (PubMed ID: 11745237)
1. A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar).
Bates S; Kang M; Meadows B; Bakke S; Choyke P; Merino M; Goldspiel B; Chico I; Smith T; Chen C; Robey R; Bergan R; Figg WD; Fojo T
Cancer; 2001 Sep; 92(6):1577-90. PubMed ID: 11745237
[TBL] [Abstract][Full Text] [Related]
2. A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma.
Bates SE; Bakke S; Kang M; Robey RW; Zhai S; Thambi P; Chen CC; Patil S; Smith T; Steinberg SM; Merino M; Goldspiel B; Meadows B; Stein WD; Choyke P; Balis F; Figg WD; Fojo T
Clin Cancer Res; 2004 Jul; 10(14):4724-33. PubMed ID: 15269145
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833.
Chico I; Kang MH; Bergan R; Abraham J; Bakke S; Meadows B; Rutt A; Robey R; Choyke P; Merino M; Goldspiel B; Smith T; Steinberg S; Figg WD; Fojo T; Bates S
J Clin Oncol; 2001 Feb; 19(3):832-42. PubMed ID: 11157037
[TBL] [Abstract][Full Text] [Related]
4. Initial pharmacokinetics and bioavailability of PSC 833, a P-glycoprotein antagonist.
Lush RM; Meadows B; Fojo AT; Kalafsky G; Smith HT; Bates S; Figg WD
J Clin Pharmacol; 1997 Feb; 37(2):123-8. PubMed ID: 9055138
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine.
Braybrooke JP; Vallis KA; Houlbrook S; Rockett H; Ellmén J; Anttila M; Ganesan TS; Harris AL; Talbot DC
Cancer Chemother Pharmacol; 2000; 46(1):27-34. PubMed ID: 10912574
[TBL] [Abstract][Full Text] [Related]
6. Phase I-II study of vinblastine and oral cyclosporin A in metastatic renal cell carcinoma.
Warner E; Tobe SW; Andrulis IL; Pei Y; Trachtenberg J; Skorecki KL
Am J Clin Oncol; 1995 Jun; 18(3):251-6. PubMed ID: 7747714
[TBL] [Abstract][Full Text] [Related]
7. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G
Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128
[TBL] [Abstract][Full Text] [Related]
8. Efflux of rhodamine from CD56+ cells as a surrogate marker for reversal of P-glycoprotein-mediated drug efflux by PSC 833.
Robey R; Bakke S; Stein W; Meadows B; Litman T; Patil S; Smith T; Fojo T; Bates S
Blood; 1999 Jan; 93(1):306-14. PubMed ID: 9864175
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group.
O'Brien MM; Lacayo NJ; Lum BL; Kshirsagar S; Buck S; Ravindranath Y; Bernstein M; Weinstein H; Chang MN; Arceci RJ; Sikic BI; Dahl GV
Pediatr Blood Cancer; 2010 May; 54(5):694-702. PubMed ID: 20209646
[TBL] [Abstract][Full Text] [Related]
10. Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi.
Chen CC; Meadows B; Regis J; Kalafsky G; Fojo T; Carrasquillo JA; Bates SE
Clin Cancer Res; 1997 Apr; 3(4):545-52. PubMed ID: 9815718
[TBL] [Abstract][Full Text] [Related]
11. Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia.
Sonneveld P; Burnett A; Vossebeld P; Ben-Am M; Rosenkranz G; Pfister C; Verhoef G; Dekker A; Ossenkoppele G; Ferrant C; Yin L; Gratwohl A; Kovacsovics T; Vellenga E; Capdeville R; Löwenberg B
Hematol J; 2000; 1(6):411-21. PubMed ID: 11920222
[TBL] [Abstract][Full Text] [Related]
12. Dexverapamil to modulate vinblastine resistance in metastatic renal cell carcinoma.
Mickisch GH; Noordzij MA; vd Gaast A; Gebreamlack P; Köhrmann KU; Mogler-Drautz E; Kupper H; Schröder FH
J Cancer Res Clin Oncol; 1995; 121 Suppl 3():R11-6. PubMed ID: 8698736
[TBL] [Abstract][Full Text] [Related]
13. High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine.
Trump DL; Smith DC; Ellis PG; Rogers MP; Schold SC; Winer EP; Panella TJ; Jordan VC; Fine RL
J Natl Cancer Inst; 1992 Dec; 84(23):1811-6. PubMed ID: 1359155
[TBL] [Abstract][Full Text] [Related]
14. Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors.
Patnaik A; Warner E; Michael M; Egorin MJ; Moore MJ; Siu LL; Fracasso PM; Rivkin S; Kerr I; Litchman M; Oza AM
J Clin Oncol; 2000 Nov; 18(21):3677-89. PubMed ID: 11054441
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T
Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757
[TBL] [Abstract][Full Text] [Related]
16. A phase I/II study of alternating constant rate infusion floxuridine with constant rate infusion vinblastine for the treatment of metastatic renal cell carcinoma.
Small EJ; Frye JW; Wilkinson MJ; Carroll PR; Ernest ML; Stagg RJ
Cancer; 1994 Jun; 73(11):2803-7. PubMed ID: 8194022
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine.
Abraham J; Edgerly M; Wilson R; Chen C; Rutt A; Bakke S; Robey R; Dwyer A; Goldspiel B; Balis F; Van Tellingen O; Bates SE; Fojo T
Clin Cancer Res; 2009 May; 15(10):3574-82. PubMed ID: 19417029
[TBL] [Abstract][Full Text] [Related]
18. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study.
Sonneveld P; Marie JP; Huisman C; Vekhoff A; Schoester M; Faussat AM; van Kapel J; Groenewegen A; Charnick S; Zittoun R; Löwenberg B
Leukemia; 1996 Nov; 10(11):1741-50. PubMed ID: 8892677
[TBL] [Abstract][Full Text] [Related]
19. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study.
Samuels BL; Hollis DR; Rosner GL; Trump DL; Shapiro CL; Vogelzang NJ; Schilsky RL
Clin Cancer Res; 1997 Nov; 3(11):1977-84. PubMed ID: 9815587
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance.
Advani R; Fisher GA; Lum BL; Hausdorff J; Halsey J; Litchman M; Sikic BI
Clin Cancer Res; 2001 May; 7(5):1221-9. PubMed ID: 11350887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
